Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLXWEL 27 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus rates XWEL with a GF Score™ of 27/100 and a GF Value™ of $0.86 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, XWELL ranks worse than 1612901.61% on this metric.
XWELL's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for XWELL's 5-Year Yield-on-Cost % or its related term are showing as below:
XWEL's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.435 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
XWELL 5-Year Yield-on-Cost % Related Terms
XWEL vs MBAI, NDRA, BIAF: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, XWELL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where XWELL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of XWELL is calculated as
XWELL (XWEL) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on XWELL and its competitors. According to the industry distribution chart, XWELL ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is XWELL's 5-Year Yield-on-Cost % too high?
XWELL's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, XWELL ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, XWELL has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XWELL's 5-Year Yield-on-Cost % compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #999999 out of 62 companies for 5-Year Yield-on-Cost %. This places XWELL in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on XWELL and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XWELL's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
Based on GuruFocus' analysis, XWELL (XWEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.86, compared to a current price of $1.04 — trading 20.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For XWELL (XWEL), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (XWEL) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of $1.04 is trading 20.9% above its estimated GF Value™ of $0.86.
GuruFocus considers XWELL to be Modestly Overvalued.
Key valuation signals for XWEL:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.86 vs. price of $1.04 (20.9% above fair value)
No single metric tells the full story. See the XWEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for XWEL
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XWEL has been successfully added to your 
